Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
— Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran — — Acceptable Safety Profile Supporting Further Development —